BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
346.73
+11.05 (+3.29%)
As of 2:10PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close335.68
Open343.12
Bid346.04 x 100
Ask346.13 x 200
Day's Range339.69 - 348.65
52 Week Range244.28 - 348.65
Volume1,098,049
Avg. Volume1,265,795
Market Cap73.31B
Beta0.47
PE Ratio (TTM)22.75
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Biogen Biomarkers Mark Way To Alzheimer's, Parkinson's Treatments
    Investor's Business Daily2 hours ago

    Biogen Biomarkers Mark Way To Alzheimer's, Parkinson's Treatments

    Biogen eyes therapies for Parkinson's, Alzheimer's and more using biomarkers, biological mechanisms and other cutting-edge technologies.

  • Should You Expect Biogen Inc (BIIB) To Continue Delivering An ROE Of 28.62%?
    Simply Wall St.2 hours ago

    Should You Expect Biogen Inc (BIIB) To Continue Delivering An ROE Of 28.62%?

    With an ROE of 28.62%, Biogen Inc (NASDAQ:BIIB) outpaced its own industry which delivered a less exciting 15.86% over the past year. While the impressive ratio tells us that BIIBRead More...

  • 3 Drug Stocks Hitting 52-Week Highs: Are They Buys?
    Motley Fool7 hours ago

    3 Drug Stocks Hitting 52-Week Highs: Are They Buys?

    2017 has been a great year for these drug stocks. But will their momentum taper off?

  • Barrons.comyesterday

    [$$] More Biotechs That Can Beat Q3 Views

    Credit Suisse Overall, we think most U.S. biotech companies look to be in-line-to-above consensus estimates. Where we have conviction and are focused into quarter: We think Biogen (BIIB) has potential to beat based mostly on Spinraza U.S. trends after reviewing a recent slide deck from the CureSMA website.

  • 6 Top Biotech Companies In Innovation Earn Recognition In New Awards
    Investor's Business Dailyyesterday

    6 Top Biotech Companies In Innovation Earn Recognition In New Awards

    Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?

  • This No. 1-Ranked Medical Stock Is Breaking Out With Q3 Earnings Due
    Investor's Business Daily4 days ago

    This No. 1-Ranked Medical Stock Is Breaking Out With Q3 Earnings Due

    Clinical research firm PRA Health Sciences is testing a new breakout move.

  • Barrons.com4 days ago

    Can Biotech Stay Healthy Through the End of 2017?

    Credit Suisse's Alethia Young and her team take a look at the biotech sector ahead of earnings, writing that they expect large-cap companies' strength to continue through the end of the year. Young writes that she expects most companies to be either in-line or above consensus estimates when they report third-quarter results, as large cap biotechs have been strong heading into t he third quarter. Among stocks where she has the most conviction in the quarter, she thinks that Biogen (BIIB) can beat expectations thanks to Spinraza (it's spinal muscular atrophy drug) trends in the U.S. She writes that she thinks investors should expect a "solid" quarter from Bioverativ (BIVV) as well, and will also be  focusing on sales from Regeneron's (REGN) Dupixent and Gilead's (GILD) HCV franchise.

  • Investopedia5 days ago

    Celgene, Biogen Are Poised to Break Out: A Technical View

    After a period of consolidation, the biotech sector is set to rise again based on technical analysis.

  • Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
    Zacks6 days ago

    Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit

    With third quarter earnings round the corner, it was a relatively slow week with key updates including Regeneron (REGN) and partner Sanofi's win in the PCSK9 litigation.

  • 5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
    Zacks7 days ago

    5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings

    Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.

  • Better Buy: Biogen Inc. vs. Celgene
    Motley Fool7 days ago

    Better Buy: Biogen Inc. vs. Celgene

    Which one of these large-cap biotech stocks looks like a better pick right now?

  • Market Realist8 days ago

    How Did Biogen Perform in 1H17?

    In 1H17, Biogen (BIIB) generated revenues of ~$5.9 billion compared to $5.6 billion in 1H16.

  • See what the IHS Markit Score report has to say about Biogen Inc.
    Markit8 days ago

    See what the IHS Markit Score report has to say about Biogen Inc.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $6.14 billion.

  • Market Realist8 days ago

    Analysts’ Recommendations for Biogen in October 2017

    Of the 29 analysts covering Biogen (BIIB) in October 2017, six analysts recommended a “strong buy,” 12 analysts recommended a “buy,” and 11 analysts recommended a “hold.” Biogen didn't receive any “sell” ...

  • Market Realist11 days ago

    Why Biogen and L Brands Rose on October 5

    Biogen (BIIB) was one of the top gainers in the S&P 500 on October 5. After trading with mixed sentiment in the first three trading days of the week, Biogen opened higher on Thursday.

  • Benzinga11 days ago

    Life (Science) Lessons: The Hows And Whos To Play Biotech

    Biotech is booming. After particularly rough endings to 2015 and 2016, iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) has had “a rockstar of a year,” and the last two weeks, in particular, have ...

  • No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock
    InvestorPlace11 days ago

    No Side Effects to This Bullish Trade on Celgene Corporation (CELG) Stock

    Yesterday, Celgene Corporation (NASDAQ:CELG) caught a downgrade and the stock fell 4% on the headline. To do this, I use CELG options instead of trading its underlying equity. Click to Enlarge Fundamentally, Celgene is not cheap.

  • Barrons.com11 days ago

    [$$] Get Back Into Biogen

    Biogen (BIIB:Nasdaq) By Morgan Stanley ($314.92, Oct. 5, 2017) We are upgrading Biogen to Overweight from Equal-weight and raising the price target to $375 from $311, as we believe the base business is proving more durable than expected with Ocrevus share loss slower than expected. Business development provides upside optionality while Alzheimer’s remains the key, must-own catalyst. Biogen (BIIB) has been a complicated story with uncertainty about its base business, which is facing potential market share and pricing pressure offset by a Phase 3 Alzheimer’s catalyst that could make all its potential issues disappear.

  • Netflix Breaks Out While Homebuilders Add To Rally
    Investor's Business Daily12 days ago

    Netflix Breaks Out While Homebuilders Add To Rally

    Netflix made a record high Thursday as the stock broke out past a new buy point in energetic trading.

  • Barrons.com12 days ago

    Biotech: Buy Biogen, Sell Celgene

    Morgan Stanley's Matthew Harrison and his team take a look at biotech today, writing that investors should buy Biogen (BIIB) rather than Celgene (CELG). Harrison upgraded Biogen to Overweight from Equal Weight, and raised his price target from $311 to $375, writing that the company's base business is more durable than he anticipated, as its multiple sclerosis treatment, Ocrevus, is losing market share more slowly than expected. In addition, he sees Spinraza, Biogen's spinal muscular atrophy drug, as worth potentially $4 billion, a fact that's under-appreciated by the market, and writes that the company's Alzheimer's business "remains the key, must-own catalyst.

  • 12 days ago

    Celgene and Biogen Analyst Moves Are 'Useless,' Jim Cramer Says

    Morgan Stanley analysts upgraded shares of Biogen and downgraded shares of Celgene over concerns of generic drug pressures. TheStreet's Jim Cramer called these moves "useless."

  • Catabasis' DMD Candidate Slows Disease Progression, Stock Up
    Zacks12 days ago

    Catabasis' DMD Candidate Slows Disease Progression, Stock Up

    Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.

  • Barrons.com12 days ago

    3 Biotechs to Buy Ahead of Q3 Earnings

    With third-quarter earnings season just around the corner, Bernstein's Aaron (Ronny) Gal and his team take a look at the biotech sector with an eye toward upcoming reports. As for specific stocks, he has Outperform ratings on Biogen (BIIB), Allergan (AGN) and Mylan (MYL). Allergan reminded us EPS should be similar to 2Q17 ($4.02) and with hurricanes probably come close (BERN: $4.04, -4c).

  • It's Friday the 13th, and these are 4 freaky good stocks ...
    CNBC Videos4 days ago

    It's Friday the 13th, and these are 4 freaky good stocks ...

    The “Fast Money” traders share their final trades for the day including Viacom, Biogen, Square and McDonald's.

  • Bernstein analyst breaks down his best biotech picks
    CNBC Videos11 days ago

    Bernstein analyst breaks down his best biotech picks

    Ronny Gal, Bernstein senior analyst, discusses his top biotech picks to buy ahead of earnings.